IMMUNOELECTRON MICROSCOPIC STUDY OF HTLV-I-PRODUCING HUMAN LYMPHOCYTES IN VITRO (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

IMMUNOELECTRON MICROSCOPIC STUDY OF HTLV-I-PRODUCING HUMAN LYMPHOCYTES IN VITRO (MEETING ABSTRACT)

Proc Annu Meet Am Assoc Cancer Res; 32:A1861 1991. Unique Identifier : AIDSLINE ICDB/91674663
Ohtsuki Y; Iwata J; Oka T; Furihata M; Sonobe H; Miyoshi I; Dept. of Pathology, Kochi Medical Sch., Kochi 783, Japan

Abstract: HTLV-I-producing human lymphoid cell lines, derived from ATL and HAM patients, and lymphocytes from HTLV-I carriers and seronegative healthy individuals were tested for lymphocyte markers, on the viral envelope and the plasma membrane. Short-term cultured lymphocytes from HTLV-I carriers, but not the virus were labeled with CD4. In the MT-2 cell line, still retaining the lymphocyte-transforming ability, both HTLV-I virions and plasma membranes were strongly positive for OKIa1 or HLA-D and CD25, but not for CD3, 5, WT-31 and beta F1. Beta F1 gave positive immunoreactivity with the perinuclear space and rough endoplasmic reticulum in some cultured lymphocytes from HTLV-I carriers, seronegative normal individuals and HAM-derived cells. Some of these cells also showed surface labeling with WT-31. These results indicate that expression of HLA-D and CD25 but not pan-T cell antigens such as CD3 and CD5 on the viral envelope is necessary for lymphocyte transformation and that the viral envelope is negative for alpha/beta chain expression of T-cell receptors.

Keywords: Antigens, CD/ANALYSIS Cell Line Cell Membrane/IMMUNOLOGY/ULTRASTRUCTURE Cells, Cultured Human HLA-D Antigens/ANALYSIS HTLV-I/*ISOLATION & PURIF/ULTRASTRUCTURE Lymphocytes/IMMUNOLOGY/MICROBIOLOGY/*ULTRASTRUCTURE Microscopy, Immunoelectron Virion/ISOLATION & PURIF/ULTRASTRUCTURE ABSTRACT
910730
M9170996

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .